Pfizer Inc.-Product Pipeline Review-2015

Pfizer Inc.-Product Pipeline Review-2015

  • Products Id :- GMDHC06903CDB
  • |
  • Pages: 390
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Pfizer Inc.-Product Pipeline Review-2015


Global Markets Direct's, 'Pfizer Inc.-Product Pipeline Review-2015', provides an overview of the Pfizer Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Pfizer Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides brief overview of Pfizer Inc. including business description, key information and facts, and its locations and subsidiaries

The report reviews current pipeline of Pfizer Inc.'s human therapeutic division and enlists all their major and minor projects

The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones

Special feature on out-licensed and partnered product portfolio

The report summarizes all the dormant and discontinued pipeline projects

Latest company statement

Latest news and deals relating to the Pfizer Inc.'s pipeline products

Reasons To Buy

Evaluate Pfizer Inc.'s strategic position with total access to detailed information on its product pipeline

Assess the growth potential of Pfizer Inc. in its therapy areas of focus

Identify new drug targets and therapeutic classes in the Pfizer Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas

Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps

Develop strategic initiatives by understanding the focus areas of Pfizer Inc. and exploit collaboration and partnership opportunities

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Plan mergers and acquisitions effectively by identifying the most promising pipeline of Pfizer Inc.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Explore the dormant and discontinued projects of Pfizer Inc. and identify potential opportunities in those areas

Avoid Intellectual Property Rights related issues

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 7

Pfizer Inc. Snapshot 8

Pfizer Inc. Overview 8

Key Information 8

Key Facts 8

Pfizer Inc.-Research and Development Overview 9

Key Therapeutic Areas 9

Pfizer Inc.-Pipeline Review 21

Pipeline Products by Stage of Development 21

Pipeline Products-Monotherapy 22

Pipeline Products-Combination Treatment Modalities 23

Pipeline Products-Partnered Products 24

Pipeline Products-Out-Licensed Products 27

Pfizer Inc.-Pipeline Products Glance 31

Pfizer Inc.-Late Stage Pipeline Products 31

Pfizer Inc.-Clinical Stage Pipeline Products 36

Pfizer Inc.-Early Stage Pipeline Products 42

Pfizer Inc.-Drug Profiles 45

(oxycodone hydrochloride + naltrexone) ER 45

(piperacillin sodium + tazobactam sodium) 47

bazedoxifene acetate 48

crizotinib 49

tofacitinib 52

tafamidis meglumine 56

adalimumab biosimilar 58

axitinib 59

bevacizumab biosimilar 62

bococizumab 63

bosutinib 64

dacomitinib 66

diazepam 68

ertugliflozin 69

gosogliptin 70

infliximab biosimilar 71

inotuzumab ozogamicin 72

meningococcal meningitis [serotype B] vaccine 74

palbociclib 76

pregabalin 80

pregabalin CR 82

rituximab biosimilar 83

rivipansel sodium 84

sildenafil citrate 86

sunitinib malate 88

trastuzumab biosimilar 92

agatolimod sodium 93

ascrinvacumab 96

Dekavil 97

fosdagrocorat 98

glasdegib 99

MultiStem 101

PF-00489791 104

PF-00547659 105

PF-02545920 107

PF-03084014 108

PF-03715455 109

PF-04236921 110

PF-04457845 111

PF-04634817 112

PF-04937319 113

PF-04965842 115

PF-05089771 116

PF-05175157 118

PF-05212377 119

PF-06252616 120

PF-06290510 121

PF-06291874 123

PF-06372865 124

PF-06425090 125

PF-06473871 126

ponezumab 128

tanezumab 130

temsirolimus 132

ziprasidone hydrochloride 134

gedatolisib 135

PF-06463922 137

PF-06747775 139

celecoxib 140

HIV vaccine 142

KUX-1151 143

PD-0325901 + PF-05212384 144

PF-04518600 145

PF-04958242 146

PF-05082566 147

PF-05206388 148

PF-05230907 149

PF-05280602 150

PF-05402536 151

PF-06260414 152

PF-06263276 153

PF-06263507 154

PF-06273340 155

PF-06282999 156

PF-06293620 157

PF-06342674 158

PF-06409577 159

PF-06412562 160

PF-06413367 161

PF-06427878 162

PF-06444752 163

PF-06444753 164

PF-06480605 165

PF-06647020 166

PF-06647263 167

PF-06648671 168

PF-06649751 169

PF-06650808 170

PF-06650833 171

PF-06651600 172

PF-06664178 173

PF-06669571 174

PF-06678552 175

PF-06687859 176

PF-06700841 178

PF-4447943 179

Antibody to Antagonize IL-7 Receptor for Type 1 Diabetes 180

Biologics for Undisclosed Indication 181

Biologics to Target PCSK-9 for Undisclosed Indication 182

CE-355621 183

Drugs for Duchenne Muscular Dystrophy 184

GIBH-1008 185

GIBH-1010 186

GIBH-1018 187

GL-2045 188

HSD-621 189

Monoclonal Antibodies for Solid Tumor 190

NIC7-DT 191

NOX-B11 192

PF-06380101 193

PF-06447475 194

PF-2988403 195

PF-3306138 196

PF-3826719 197

PF-3845 198

PF-4942847 199

PF-4989216 200

PF-5006739 201

PNU-120596 202

Proteins to Agonize MC4R for Obesity 203

RBT-301 204

Small Molecule for Neurological Disorders 205

Small Molecule to Antagonize Tie-2 Receptor for Solid Tumor 206

Small Molecule to Inhibit HPGDS for Asthma 207

Small Molecule to Inhibit IDO1 for Cancer 208

Small Molecule to Inhibit Lipopolysaccharide for Nosocomial Infections 209

Small Molecule to Inhibit TDO-2 for Cancer 210

Small Molecule to Modulate Androgen Receptor for Muscle Disorders 212

Small Molecules to Activate CFTR for Cystic Fibrosis 213

Small Molecules to Inhibit NMT for Malaria 214

Small Molecules to Inhibit PDE2 for Osteoarthritis Pain 215

Vaccine 2 for Undisclosed Indication 216

Antisense Oligonucleotide for Undisclosed Indication 217

Drug to Agonize Melanocortin Receptor 3 for Rheumatoid Arthritis and Inflammation 218

Monoclonal Antibody Conjugate for Cancer 219

Monoclonal Antibody Conjugates for Oncology 220

PF-00190434 221

PF-04445597 222

PF-2311200 223

PF-2345185 224

PF-2614170 225

PF-3604861 226

PF-3686093 227

PF-46396 228

PPD-1 229

Small Molecule to Agonize LXR for Inflammation 230

Small Molecule to Antagonize Ghrelin for Alcoholism 231

Small Molecule to Antagonize Melanocortin Receptor 2 for Cushing's Disease 232

Small Molecule to Inhibit NS5A for HCV 233

Small Molecule to Inhibit PI3K and mTOR for Cancer 234

Small Molecule to Inhibit Pin1 for Cancer 235

Small Molecule to Target AGTR1 and PPAR gamma for Hypertension and Metabolic Syndrome 236

Small Molecules for Inflammatory and Orphan Diseases 237

Small Molecules for Obesity and Diabetes 238

Small Molecules for Ulcerative Colitis and Crohn's Disease 239

Small Molecules to Agonize A1 Adenosine Receptor for Undisclosed Indication 240

Pfizer Inc.-Pipeline Analysis 241

Pfizer Inc.-Pipeline Products by Target 241

Pfizer Inc.-Pipeline Products by Route of Administration 248

Pfizer Inc.-Pipeline Products by Molecule Type 249

Pfizer Inc.-Pipeline Products by Mechanism of Action 250

Pfizer Inc.-Recent Pipeline Updates 256

Pfizer Inc.-Dormant Projects 307

Pfizer Inc.-Discontinued Pipeline Products 314

Discontinued Pipeline Product Profiles 319

Pfizer Inc.-Company Statement 342

Pfizer Inc.-Locations And Subsidiaries 347

Head Office 347

Other Locations & Subsidiaries 347

Appendix 374

Methodology 374

Coverage 374

Secondary Research 374

Primary Research 374

Expert Panel Validation 374

Contact Us 374

Disclaimer 375

List of Tables

Pfizer Inc., Key Information 23

Pfizer Inc., Key Facts 23

Pfizer Inc.-Pipeline by Indication, 2015 25

Pfizer Inc.-Pipeline by Stage of Development, 2015 36

Pfizer Inc.-Monotherapy Products in Pipeline, 2015 37

Pfizer Inc.-Combination Treatment Modalities in Pipeline, 2015 38

Pfizer Inc.-Partnered Products in Pipeline, 2015 39

Pfizer Inc.-Partnered Products/ Combination Treatment Modalities, 2015 40

Pfizer Inc.-Out-Licensed Products in Pipeline, 2015 42

Pfizer Inc.-Out-Licensed Products/ Combination Treatment Modalities, 2015 43

Pfizer Inc.-Pre-Registration, 2015 46

Pfizer Inc.-Filing rejected/Withdrawn, 2015 47

Pfizer Inc.-Phase III, 2015 48

Pfizer Inc.-Phase II, 2015 51

Pfizer Inc.-Phase I, 2015 54

Pfizer Inc.-Preclinical, 2015 57

Pfizer Inc.-Discovery, 2015 59

Pfizer Inc.-Pipeline by Target, 2015 257

Pfizer Inc.-Pipeline by Route of Administration, 2015 263

Pfizer Inc.-Pipeline by Molecule Type, 2015 264

Pfizer Inc.-Pipeline Products by Mechanism of Action, 2015 265

Pfizer Inc.-Recent Pipeline Updates, 2015 271

Pfizer Inc.-Dormant Developmental Projects,2015 322

Pfizer Inc.-Discontinued Pipeline Products, 2015 329

Pfizer Inc., Other Locations 362

Pfizer Inc., Subsidiaries 362

List of Figures

Pfizer Inc.-Pipeline by Top 10 Indication, 2015 25

Pfizer Inc.-Pipeline by Stage of Development, 2015 36

Pfizer Inc.-Monotherapy Products in Pipeline, 2015 37

Pfizer Inc.-Combination Treatment Modalities in Pipeline, 2015 38

Pfizer Inc.-Partnered Products in Pipeline, 2015 39

Pfizer Inc.-Out-Licensed Products in Pipeline, 2015 42

Pfizer Inc.-Pipeline by Top 10 Target, 2015 256

Pfizer Inc.-Pipeline by Top 10 Route of Administration, 2015 263

Pfizer Inc.-Pipeline by Top 10 Molecule Type, 2015 264

Pfizer Inc.-Pipeline Products by Top 10 Mechanism of Action, 2015 265

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]

Current R&D Portfolio of Pfizer Inc.; Pfizer Inc. - Key Therapeutics; Pfizer Inc. - Pipeline Overview and Promising Molecules; Pfizer Inc. - News; Pfizer Inc. - Latest Updates; Pfizer Inc. - Pipeline; Pfizer Inc. - Discontinued/Dormant Projects

select a license
Single User License
USD 1500 INR 107670
Site License
USD 3000 INR 215340
Corporate User License
USD 4500 INR 323010



An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]